precis
mechan
sever
acut
respiratori
syndrom
sar
caus
sarsassoci
coronaviru
sarscov
still
unclear
gener
recombin
vaccinia
viru
rvv
strain
simultan
express
four
structur
protein
sarscov
includ
nucleocapsid
n
membran
envelop
e
spike
protein
rvvnme
report
old
balbc
mice
prior
immun
rvvnme
develop
sever
pneumonia
similar
control
mice
though
rvvnmesimmun
mice
show
lower
pulmonari
viral
titer
control
mice
furthermor
determin
sarscov
structur
protein
prior
rvvimmun
respons
sever
pneumonia
sarscov
infect
observ
rvvnmesimmun
mice
old
balbc
mice
inocul
intraderm
rvv
express
structur
protein
sarscov
rvvn
e
without
rvv
infect
intranas
sarscov
week
later
day
sarscov
infect
rvvnimmun
mice
show
sever
pneumonia
group
furthermor
signific
upregul
bia
cytokin
downregul
antiinflammatori
cytokin
tgf
observ
rvvnimmun
mice
result
intens
infiltr
immunocompet
cell
lung
contrast
rvvsimmun
mice
show
low
pulmonari
viral
tier
slight
pneumonia
howev
mice
coimmun
rvvn
rvv
show
sever
pneumonia
though
pulmonari
viral
titer
low
result
suggest
excess
host
immun
respons
n
protein
sarscov
involv
sever
pneumonia
caus
sarscov
infect
find
increas
understand
pathogenesi
sar
novemb
juli
outbreak
sever
acut
respiratori
syndrom
sar
origin
china
spread
worldwid
result
case
death
http
wwwwhointcsrsarscountryenindexhtml
patient
sar
usual
develop
high
fever
follow
sever
clinic
symptom
includ
acut
respiratori
distress
syndrom
diffus
alveolar
damag
dad
ultim
die
novel
type
coronaviru
term
sarsassoci
coronaviru
sarscov
identifi
etiolog
agent
sar
angiotensinconvert
enzym
identifi
host
receptor
sarscov
abundantli
express
epithelia
lung
small
intestin
may
mediat
sarscov
entri
human
although
intens
investig
rapidli
unravel
sequenc
sarscov
genom
receptor
human
precis
molecular
mechan
underli
develop
sar
fulli
understood
possibl
role
host
antisarscov
immun
respons
suggest
sever
clinic
case
uncontrol
releas
immun
mediat
call
cytokin
storm
implic
pathogenesi
sar
howev
cytokin
profil
sar
patient
sera
correl
sever
pneumonia
divers
result
might
relat
patient
anamnesi
therefor
develop
anim
model
sar
need
understand
pathogenesi
sar
recent
robert
et
al
report
age
balbc
mice
older
month
exhibit
high
prolong
level
viral
replic
sign
clinic
symptom
histopatholog
chang
lung
age
balbc
mice
repres
convent
analysi
mechan
balbc
mice
prior
immun
nucleocapsid
protein
sarscov
develop
sever
pneumonia
sarscov
infect
anim
model
mimic
find
elderli
sar
patient
mani
exhibit
sever
diseas
requir
intens
care
ventil
support
well
increas
mortal
present
studi
investig
pulmonari
immun
respons
patholog
intranas
sarscovinfect
balbc
mice
month
age
previous
immun
sarscov
structur
protein
use
vaccinia
viru
vector
gener
plasmid
vector
pbmsf
express
transgen
control
synthet
hybrid
promot
homolog
recombin
hemagglutinin
ha
locu
vaccinia
viru
strain
briefli
transgen
encod
sarscov
structur
protein
ligat
insert
intern
ribosom
entri
site
ire
sequenc
hepat
c
viru
fuse
sequenc
foot
mouth
diseas
viru
fmdv
thosea
asigna
viru
tav
encephalomyocard
viru
emcv
pcr
fig
gener
dna
fragment
digest
ecori
insert
downstream
hybrid
promot
pbmsf
therebi
gener
pbmsfsarsnm
pbmsfsarsnm
plasmid
linear
pvui
transfect
primari
rabbit
kidney
prk
cell
infect
multipl
infect
moi
h
viruscel
mixtur
harvest
scrape
frozen
use
result
haneg
recombin
virus
purifi
describ
previous
name
furthermor
recombin
vaccinia
viru
mo
express
sarscov
n
e
protein
sixhistidin
tag
cterminu
gener
morvvnhi
mhi
ehi
mo
express
sixhistidinetag
protein
morvvshi
describ
previous
femal
balbc
mice
age
month
use
studi
four
group
balbc
mice
per
group
inocul
intraderm
either
pfubodi
l
vehicl
mem
without
fc
wk
postimmun
mice
infect
intranas
tcid
bodi
sarscov
lmous
describ
previous
mice
sacrif
anesthesia
lung
liver
small
intestin
spleen
extirp
day
day
later
aliquot
tissu
frozen
immedi
c
fix
formalin
collect
blood
use
vitro
neutral
assay
addit
balbc
mice
inject
intraderm
pfubodi
rvv
express
structur
protein
sarscov
morvvn
e
without
ie
e
alon
e
infect
tcid
bodi
sarscov
wk
later
day
day
mice
per
group
sacrif
follow
blood
collect
anesthesia
lung
extirp
anim
experi
use
mice
approvedbi
anim
experimentcommitte
institut
medic
scienc
univers
tokyo
perform
accord
anim
experiment
guidelin
institut
medic
scienc
univers
tokyo
sarscov
titer
mous
organ
determin
describ
previous
serial
dilut
supernat
lung
homogen
ad
vero
cell
seed
plate
day
incub
cell
fix
formalin
viral
titer
determin
endpoint
dilut
homogen
induc
cytopath
effect
method
use
endpoint
calcul
describ
reed
muench
ten
formalinfix
lung
tissu
sarscovinfect
mice
embed
paraffin
paraffin
block
section
thick
stain
hematoxylin
eosin
stain
evalu
pulmonari
patholog
use
histopatholog
score
system
develop
cimolai
et
al
measur
level
cytokinechemokin
mrna
total
rna
sampl
extract
lung
use
rneasi
mini
kit
qiagen
quantit
rtpcr
carri
taqman
gene
express
assay
appli
biosystem
foster
citi
ca
use
abi
prism
sequenc
detect
system
softwar
ver
foldchang
copi
number
cytokinechemokin
mrna
reveal
use
ct
method
use
rrna
endogen
calibr
use
attenu
vaccinia
viru
strain
gener
recombin
vaccinia
viru
multicistron
transgen
express
simultan
four
structur
protein
sarscov
n
e
protein
inocul
intraderm
back
balbc
mice
pfubodi
wk
singl
immun
mice
infect
intranas
sarscov
tcid
bodi
fig
day
sarscov
infect
sever
pulmonari
inflamm
observ
balbc
mice
fig
howev
initi
viru
titer
significantli
lower
control
group
includ
vehicleand
mice
fig
sever
pulmonari
inflamm
correl
viru
titer
mice
contrast
correl
observ
vehicl
group
day
postinfect
group
could
elicit
significantli
neutral
antibodi
sarscov
control
group
data
shown
allevi
sarscov
infect
result
suggest
sever
pulmonari
inflamm
seen
mice
sarscov
infect
result
host
immun
respons
rather
direct
cytopath
effect
sarscov
sinc
viru
titer
group
neglig
day
sarscov
infect
viru
titer
group
significantli
decreas
day
postinfect
hypothes
sever
pulmonari
inflamm
seen
mice
result
host
immun
respons
sarscov
compon
express
therefor
investig
influenc
rvv
express
structur
protein
sarscov
morvvn
e
subsequ
intranas
infect
sarscov
balbc
mice
immun
morvvn
e
pfubodi
wk
later
infect
intraderm
tcid
sarscov
fig
consist
result
signific
reduct
pulmonari
viru
titer
observ
day
morvvsimmun
group
fig
contrast
immun
sarscov
structur
protein
includ
n
e
protein
confer
protect
subsequ
sarscov
infect
allevi
pulmonari
inflamm
also
observ
morvvsimmun
group
fig
sever
infiltr
lymphocyt
thicken
alveolar
epithelia
observ
lung
tissu
morvvnimmun
mice
day
sarscov
infect
fig
pulmonari
damag
morvvnimmun
mice
significantli
sever
morvvsimmun
mice
fig
howev
signific
differ
among
group
confirm
exacerb
effect
n
protein
immun
investig
pulmonari
viru
titer
histopatholog
balbc
mice
previous
immun
combin
morvvn
morvv
morvvnsimmun
group
day
day
sarscov
infect
compar
group
includ
mo
morvvmsmorvv
morvvsimmun
group
morvvnsimmun
group
show
significantli
decreas
pulmonari
viru
titer
compar
moimmun
group
fig
howev
morvvnsimmun
group
exhibit
sever
pneumonia
moimmun
group
fig
contrast
morvvmsimmun
group
morvvesimmun
group
protect
sarscov
infect
extent
morvvsimmun
group
fig
date
studi
report
regard
sar
patient
sever
pneumonia
previous
immun
either
sarscov
highli
relat
speci
contrast
sever
report
antisera
human
coronavirus
host
factor
crossreact
sarscov
antigen
furthermor
n
protein
sarscov
shown
induc
cellular
humor
immun
respons
taken
togeth
result
rais
possibl
percentag
sar
patient
alreadi
possess
adapt
immun
respons
element
interact
sarscov
compon
includ
n
protein
adapt
immun
respons
may
involv
exacerb
pneumonia
tempor
chang
immun
respons
pathogenesi
sarscov
infect
anim
model
previous
immun
sarscov
compon
wellunderstood
almost
previou
studi
report
protect
within
day
sarscov
infect
present
studi
demonstr
morvvnimmun
mice
sarscov
infect
exhibit
imbal
tcell
activ
high
express
level
ifn
subsequ
suppress
low
express
level
tgf
well
highlevel
product
proinflammatori
cytokin
tnf
chemokin
data
shown
tgfplay
import
role
suppress
inflammatori
respons
thu
reduc
product
antiinflammatori
cytokin
morvvnimmun
mice
sarscov
infect
may
relat
sever
pulmonari
inflamm
mice
felin
infecti
periton
viru
fipv
anoth
member
coronaviru
famili
exhibit
enhanc
fipv
infect
monocytesmacrophag
virusspecif
antibodi
bind
fc
receptor
cell
caus
enhanc
inflamm
also
report
dengu
viru
secondari
infect
differ
genotyp
result
sever
symptom
includ
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
compar
moimmun
group
use
bonferroni
test
p
p
compar
morvvn
simmun
group
use
bonferroni
test
dss
exacerb
symptom
also
posit
associ
preexist
antibodi
specif
dengu
viru
case
sarscov
antibodydepend
enhanc
infect
report
previous
hypothes
sever
pneumonia
observ
morvvnimmun
mice
sarscov
infect
result
antibodydepend
enhanc
sinc
viru
titer
mous
lung
day
later
detect
limit
deme
et
al
report
recent
intens
infiltr
eosinophil
well
lymphocyt
sarscov
infect
age
balbc
mice
previous
immun
n
protein
sarscov
author
specul
respons
vaccin
host
sarscov
infect
might
aggrav
pulmonari
inflamm
although
main
host
respons
remain
unknown
contrast
current
data
suggest
n
proteinimmun
mice
exhibit
activ
respons
sarscov
infect
agreement
data
jin
et
al
demonstr
prior
immun
n
protein
gener
stronger
antigenspecif
respons
immun
e
protein
result
suggest
studi
includ
epitop
analysi
requir
reveal
precis
mechan
underli
sever
pulmonari
inflamm
result
sarscov
infect
balbc
mice
immun
n
protein
sarscov
contrast
intraderm
immun
age
balbc
mice
pfubodi
significantli
reduc
pulmonari
viru
titer
day
sarscov
infect
fig
furthermor
group
exhibit
allevi
pulmonari
histopatholog
compar
control
group
day
fig
result
suggest
system
immun
respons
induc
singl
immun
sar
vaccin
success
protect
anim
model
intranas
sarscov
infect
conclus
demonstr
immun
balbc
mice
n
protein
sarscov
caus
sever
pulmonari
inflamm
upon
subsequ
sarscov
infect
probabl
via
imbal
creat
tcell
activ
suppress
well
massiv
proinflammatori
cytokin
product
result
provid
new
insight
mechan
involv
pathogenesi
sar
help
develop
safe
vaccin
